About QMENTA

We didn't start with software. We started with the science.

Founded by researchers who lived inside the problem, QMENTA is the platform they wished had existed. A decade later, it has helped rewrite a global diagnostic standard, runs across 250+ imaging sites, and has managed over 16 million files.

View open roles →
QMENTA team, Boston and Barcelona offices
Purpose

To make brain diseases a thing of the past.

Neurological diseases cause enormous suffering extended by slow, fragmented research systems. We exist to remove that friction.

Mission

Compressing the timeline between imaging and breakthrough.

Every week lost to operational failure is a week the science falls behind. We eliminate those losses through a data layer that makes imaging data immediately reliable, usable, and submission-ready.

Vision

Science with the tools that outpace diseases that steal memory, movement, and identity.

A world where the gap between discovery and clinical practice is measured in months, not decades, and imaging is the fastest path to that translation.

Our story

Built from a frustration we lived.

Our founders Vesna and Paulo spent their PhDs watching promising science stall at the last mile. Data trapped in silos, workflows rebuilt by hand, researchers carrying CDs between sites. In 2013 they decided to build the infrastructure they'd needed themselves, regulated and cloud-native from day one, not bolted on when an audit arrived.

Our mission is to turn imaging into a connected foundation for better diagnosis and faster therapies, so a promising idea can travel from research into clinical practice in years, not decades. The central-vein sign proves it: through the CAVS-MS trial it went from a single-vendor research sequence to part of the McDonald Criteria, the global standard used to diagnose MS in every major clinical trial worldwide.

That's what it looks like when imaging infrastructure stops being an obstacle. And with AI now built into the foundation, governed from day one, it's only getting faster.

The quote that drives us
 

"We're not building software. We're building the imaging platform that makes brain diseases a thing of the past. And we've already helped rewrite how one of them gets diagnosed."

Vesna Prchkovska, PhD · CEO & Co-Founder

Why we're independent

QMENTA carries no pharmaceutical company investment. In regulated CNS and oncology trials, that independence is not a differentiator, it's a contractual and governance requirement. Your legal, compliance, and procurement teams will ask. The answer is clean.

Compliance

Built for the regulatory environment your submission requires.

✓ 510(k) Cleared ✓ FDA 21 CFR Part 11 ✓ HIPAA ✓ GDPR ✓ ISO 13485 ✓ GxP ✓ GCP-aligned

Vendor-neutral across GE HealthCare, Siemens, Philips, Canon, United Imaging, and any DICOM system

US Headquarters: 75 State Street, Suite 100, Boston MA  ·  EU Headquarters: Carrer de la Ciutat de Granada 150, Barcelona

250+
Imaging sites in production. 16M files managed. 1.3M subjects.
MIT TR35
Innovators Under 35, recognized four consecutive years.
Zero
Nonconformities in external pharma audits.
Independent
No pharmaceutical company investment. A governance requirement.

Trusted by leading sponsors, CROs, and academic medical centers

UCSF
NIH
Icon
Athinoula
Multiple MS
Amylyx
Bayer
Ruhr
Cleveland Clinic
The team

Executive Leadership

Founded by scientists. Scaled by operators. Governed by a board built for regulated, mission-critical technology.

Vesna Prchkovska, PhD, CEO and Co-Founder, QMENTA

Vesna Prchkovska, PhD

Chief Executive Officer & Co-Founder

PhD in Biomedical Engineering, TU Eindhoven. Post-doctoral researcher, IDIBAPS; visiting researcher, Harvard Medical School. Research in diffusion MRI underpins the platform's core imaging AI. MIT Technology Review Innovator Under 35.

Paulo Rodrigues, PhD, CTO and Co-Founder, QMENTA

Paulo Rodrigues, PhD

Chief Technology Officer & Co-Founder

PhD in Neuroimaging, TU Eindhoven. Co-founded Mint Labs and led the architectural vision behind QMENTA's governed cloud environment, AI orchestration layer, and DICOM-native ingestion pipelines.

David Fogel, CFO, QMENTA

David Fogel

Chief Financial Officer

Oversees financial strategy, capital structure, and operational rigor across US and European markets. Background in growth-stage healthcare technology and enterprise SaaS finance.

Governance

Board of Directors

Vesna Prchkovska, PhD

Vesna Prchkovska, PhD

Board Chair

CEO & Co-Founder, QMENTA

Paulo Rodrigues, PhD

Paulo Rodrigues, PhD

Board Member

CTO & Co-Founder, QMENTA

David Kaplan

David Kaplan

Board Member

Managing Partner, Shepherd Kaplan Krochuk

David Shepherd

David Shepherd

Board Member

Managing Partner, Shepherd Kaplan Krochuk

Peter Blaustein

Peter Blaustein

Board Member

Managing Partner, PB Investment Partners

Landon McKenna

Landon McKenna

Board Member

Co-founder

Board Observers

Roy Berggren

Roy Berggren

Board Observer

Senior Partner Emeritus, McKinsey & Company

Michael Szalontay

Michael Szalontay

Board Observer

Managing Partner, Flashpoint Venture Capital

John E. Kelly III, PhD

John E. Kelly III, PhD

Board Observer

Former Executive Vice President, IBM

Yanev Suissa

Yanev Suissa

Board Observer

Founder & Managing General Partner, SineWave Ventures

Roy Davis

Roy Davis

Board Observer

Former Corporate Vice President, Johnson & Johnson

Scientific & Strategic Advisors

The expertise behind the platform.

QMENTA's advisors include a Nobel Laureate, Harvard Medical School faculty, senior McKinsey healthcare strategists, former GE Healthcare leadership, and clinical neuroscientists who've used QMENTA in their own research.

Bruce Rosen, MD, PhD

Bruce Rosen, MD, PhD

Scientific Advisor

Professor, Harvard Medical School

Walter Gilbert, PhD

Walter Gilbert, PhD

Scientific Advisor

Nobel Laureate in Chemistry

Ajay Gupta

Ajay Gupta

Strategic Advisor

Senior Partner Emeritus, McKinsey & Company

Montserrat Barceló, MD

Montserrat Barceló, MD

Strategic Advisor

CRO Executive & Investor

Pablo Villoslada, MD, PhD

Pablo Villoslada, MD, PhD

Scientific Advisor

Clinical Neuroscientist

Glenn Thomas

Glenn Thomas

Strategic Advisor

Former CMO, GE Healthcare

Igor Bogicevic

Igor Bogicevic

Technology Advisor

Serial Technology Entrepreneur

Chris Llewellyn, MD

Chris Llewellyn, MD

Strategic Advisor

Healthcare Technology Advisor

The science behind the platform

Our science shows up in journals.

QMENTA is not a commercial overlay on third-party science. The platform was built by the researchers who published the work.

Lancet Digital Health · 2023

AI sensitivity 93.3% vs. 58.3% with standard radiology alone in MS lesion detection, validated across 397 real-world MRI pairs.

Potter et al. · n=397 real-world MRI pairs · Prospective multi-site validation

JAMA Neurology · 2013

18–25% patient misclassification rate with standard MS monitoring, the foundational finding that motivated the QMENTA platform's QC and harmonization architecture.

Sormani et al. · Foundational MS monitoring study

McDonald Criteria Revision · 2024

QMENTA's platform validated the Central Vein Sign biomarker now incorporated into the revised McDonald Criteria as the global standard for MS diagnosis.

CAVS-MS Trial · Cleveland Clinic · International panel revision

Join the mission

We're building the data layer that removes the bottleneck between imaging science and clinical impact.

If that's a problem worth solving, we'd like to talk, whether you're a potential customer, partner, or colleague.

Book a Demo